Remove Communication Remove Drug Development Remove Magazine
article thumbnail

Lisata collaborates with GATC Health on drug development

Pharmaceutical Technology

June 18, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook GATC’s MAT platform identifies potential new drugs and provides comprehensive analytic reports. Lisata Therapeutics has formed a strategic partnership with GATC Health to advance AI-driven drug discovery and development.

article thumbnail

Unpacking rare diseases in the first edition of Delta magazine

pharmaphorum

Welcome to Delta – the new Fishawack Health magazine. We’ve chosen to focus our first edition of the magazine on a topic close to our hearts, rare diseases. DOWNLOAD OUR DIGITAL MAGAZINE HERE. The post Unpacking rare diseases in the first edition of Delta magazine appeared first on.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Deep Dive: Communications and Commercialisation

pharmaphorum

The COVID-19 pandemic kickstarted a period of profound change in how the pharmaceutical industry approaches both communications and commercialisation. The pharma company’s senior vice president for major markets talks about the continued evolution of the industry’s approach to communications and commercialisation.

article thumbnail

RFK Jr looks to alter rare disease regulation by fast-tracking drug approvals

Pharmaceutical Technology

wants to ensure the ensuing the US does not lag behind other countries in drug development. We want to make sure we are getting rid of the regulatory impediments [that stop drugs getting to market],” RFK Jr stated. We may still continue to send you service-related and other non-promotional communications.

article thumbnail

EC approves argenx’s efgartigimod alfa for CIDP treatment

Pharmaceutical Technology

Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Can pharma tariffs “Make America Manufacture Again”?

article thumbnail

Actio gains $66m to advance small molecule therapeutics pipeline

Pharmaceutical Technology

Actio Biosciences CEO and co-founder David Goldstein stated: “We have made tremendous progress across our pipeline – executing a precision medicine strategy that targets the root causes of disease through genetically informed drug development. Can pharma tariffs “Make America Manufacture Again”?

article thumbnail

Harbour BioMed partners Otsuka on new T-cell therapy

Pharmaceutical Technology

We may still continue to send you service-related and other non-promotional communications. Can pharma tariffs “Make America Manufacture Again”? By Cytiva Thematic You have a right to withdraw your consent at any time, by clicking here. For more information relating to our privacy practices, we invite you to review our privacy policy.